Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.53 |
| ▸ | TDO2 | P48775 | 10/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216524 | 0.91 | GAA (0.45) | IDO1TDO2CYP2C9POLBGAA | |
| SCHEMBL21138418 | 0.89 | IDO1 (0.54) | IDO1TDO2CYP2C9POLBGAA | |
| SCHEMBL3217199 | 0.82 | SIGMAR1 (0.51) | CYP2C9CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL21138417 | 0.80 | IDO1 (0.52) | IDO1TDO2CYP2C9S1PR5CYP3A4 | |
| SCHEMBL325979 | 0.79 | S1PR5 (0.68) | S1PR5S1PR1S1PR3 | |
| SCHEMBL21138094 | 0.76 | ALDH1A1 (0.44) | IDO1TDO2CYP2C9POLBGAA | |
| SCHEMBL18657304 | 0.75 | SIGMAR1 (0.60) | CYP2C9POLBS1PR5CYP1A2CYP3A4 | |
| SCHEMBL10265035 | 0.75 | S1PR5 (0.50) | CYP2C9S1PR5CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL325502 | 0.75 | SIGMAR1 (0.58) | CYP2C9S1PR5CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL325591 | 0.75 | S1PR5 (0.50) | CYP2C9S1PR5CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | IDO1 3254/4885TDO2 4052/4885CYP2C9 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.